Compare SPRO & FCAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SPRO | FCAP |
|---|---|---|
| Founded | 2013 | 1891 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Savings Institutions |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.7M | 125.9M |
| IPO Year | 2017 | 1999 |
| Metric | SPRO | FCAP |
|---|---|---|
| Price | $2.28 | $58.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 281.7K | 24.4K |
| Earning Date | 11-13-2025 | 01-23-2026 |
| Dividend Yield | N/A | ★ 2.04% |
| EPS Growth | N/A | ★ 25.19 |
| EPS | N/A | ★ 4.41 |
| Revenue | $40,549,000.00 | ★ $47,323,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $13.78 |
| Revenue Growth | N/A | ★ 15.22 |
| 52 Week Low | $0.51 | $30.49 |
| 52 Week High | $3.22 | $71.00 |
| Indicator | SPRO | FCAP |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 52.99 |
| Support Level | $2.26 | $59.76 |
| Resistance Level | $2.37 | $61.48 |
| Average True Range (ATR) | 0.07 | 3.52 |
| MACD | -0.00 | -0.99 |
| Stochastic Oscillator | 12.12 | 15.22 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
First Capital Inc is the financial holding company of First Harrison Bank. Through its subsidiary, it operates as a federally-chartered savings bank that provides banking services to individuals and business customers across locations in America. The bank offers various loans which include residential loans, construction loans, commercial real estate loans and commercial business loans. It also provides consumer loans such as home equity and second mortgage loans, and automobile and truck loans.